NEU

0.00%

$3.75

NEUREN PHARMACEUTICALS LIMITED

Market Cap $483.6M Add to my watchlist

ASX CANNABIS LEADER

Global medical cannabis company, Althea Group holdings (ASX:AGH) furthers its presence across the EU following Irish regulatory approval of its medicinal product, CBD12:THC10.

Latest Threads

Tag

Subject

NEU

Share Price

23 24 25

08:28

1.4K

596K

08:28

Last post Guzz

1.4K

596K

NEU

Trofinitide: A Parental Case Study

23/06/22

6.1K

23/06/22

Last post Kluck

6.1K

NEU

Acadia - Catalysts Stacking

23/06/22

20K

23/06/22

Last post Vapor

20K

NEU

ANAVEX MEETS ENDPOINTS PHASE2 RETT

23/06/22

22K

23/06/22

Last post hottod

22K

NEU

NEU chart

22/06/22

17K

22/06/22

Last post moloch

17K

NEU

A Question

18/06/22

7.5K

18/06/22

Last post hottod

7.5K

NEU

Dame Margaret Brimble wins Pedler Award

10/06/22

551

10/06/22

Last post Eagle0

551

NEU

2017...2018?

3 4 5

07/06/22

250

201K

07/06/22

Last post What A Gas

250

201K

See All Discussions

Timeline

Results of Meeting
30 May 16:37	Share

AGM Chairman's Address & CEO Presentation
30 May 14:20	Share

Quarterly Activities/Appendix 4C Cash Flow Report
29 Apr 12:58	Share

Virtual AGM online guide
28 Apr 09:46	Share

Notice of Annual General Meeting/Proxy Form
28 Apr 09:40	Share

Change in substantial holding
27 Apr 16:52	Share

Appendix 4G
27 Apr 09:20	Share

Annual Report to shareholders
27 Apr 09:05	Share

FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
25 Mar 09:54	Share

FDA approval for Phelan-McDermid IND and Phase 2 trial
23 Mar 09:44	Share

Ethics approval for Angelman Phase 2 trial in Australia
11 Mar 09:33	Share

S&P DJI Announces March 2022 Quarterly Rebalance
04 Mar 17:02	Share

Investor presentation 25 Feb 2022
25 Feb 10:08	Share

FDA approval for Angelman IND and Phase 2 trial
25 Feb 09:31	Share

2021 Results - a transformational year for Neuren
24 Feb 09:36	Share

Preliminary Final Report and 2021 Full Year Accounts
24 Feb 09:31	Share

Notification regarding unquoted securities - NEU
03 Feb 17:02	Share

Neuren appoints Vice President, Corporate Development
01 Feb 09:28	Share

Q4 2021 quarterly activity and cash flow report
31 Jan 10:09	Share

Becoming a substantial holder
10 Dec 15:04	Share

Positive topline results from Phase 3 trial in Rett syndrome
07 Dec 09:48	Share

Neuren presenting at Bell Potter Healthcare Conference
10 Nov 08:58	Share

Q3 2021 quarterly activity and cash flow report
28 Oct 09:39	Share

Neuren receives feedback on IND for Phelan-McDermid syndrome
21 Oct 12:51	Share

Change of Director's Interest Notice - D Angus
20 Oct 15:29	Share

US patent to 2034 granted for Neuren's NNZ-2591 in autism
11 Oct 09:50	Share

Change of Director's Interest Notice - J Harry
08 Oct 09:32	Share

Change of Director's Interest Notice - J Pilcher
08 Oct 09:31	Share

Change of Director's Interest Notice - P Davies
08 Oct 09:30	Share

Application for quotation of securities - NEU
08 Oct 09:26	Share

View More

(20min delay) Trade with IG
Last $3.75		Change 0.000(0.00%)		Mkt cap ! $483.6M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	13	$3.93

Sellers (Offers)

Price($)	Vol.	No.
$3.55	19	1

View Market Depth

No.	Vol.	Price($)
1	1	3.740
2	2288	3.730
1	50	3.700
1	7152	3.660
1	5000	3.620

Price($)	Vol.	No.
3.550	19	1
3.620	42	2
3.730	107	1
3.800	8303	2
3.850	4963	2

Last trade - 09.50am 29/06/2022 (20 minute delay)

NEU (ASX) Chart

Day chart unavailable